A venture capital firm founded in 2022 and headquartered in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market. The firm is open to global companies, typically allocating between $250k-1.5M USD. The firm can act as a lead investor and co-investor. 
 
In terms of life science, the firm invests in cancer-focused digital health companies, however, does not invest in drugs, therapeutics, medical devices, and technologies that require FDA approval. 
 
The firm does not have specific management team requirements and does not require to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital fund founded in 2020 and headquartered in California invests in life science and healthcare companies that focus on mental health and wellness. The firm prefers to invest in Seed rounds but is open to Pre-Seed as well, with typical check sizes ranging from $500k-700k USD. The firm is open to global companies. 

The firm is open to drugs, digital health, diagnostics, and device companies with indications in psychiatry, neurology, and neuropsychiatry. Some categories of interest include psychedelic medicine & new compounds, neurotech & human augmentation, precision psychiatry, digital therapeutics, holistic medicine, metabolic psychiatry, digital health, and AI. The firm can invest as early as pre-clinical and in-development stages. 

The firm can co-lead for Pre-Seed rounds and does not require to take a board seat. The firm prefers to have at least one co-founder be full-time. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture arm of a leading global Contract Research, Development and Manufacturing Organization (CRDMO) founded in 2018 is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The venture arm does not lead rounds and prefers companies with a lead investor in place. Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The venture arm makes equity investments only and does not have an equity-for-service model. 
 
Separately from the corporate venture arm, the organizations runs a program that collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the organization’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 

The venture arm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 

The venture arm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

The venture’s team is open to meeting with companies in their initial stage of fundraising and will track their progress. But they will only look deeper into the opportunities when a lead investor is in play and the company is close to signing a term sheet.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture fund founded in 2019 with headquarters in the Bay Area, an $100M AUM, and a current fund size of $50M USD, is dedicated towards medical device-centered technologies from Series A to C. The firm is open to earlier-stage opportunities if the project aligns with the firm’s interests. The typical initial check size is $1-5M, and the firm plans to make 4-5 investments in the next year. The firm invests globally with a focus in the United States. 

The firm invests in PMA and 510K medical devices, specifically those pertaining to surgical innovation, in development and clinical phases. The firm does not invest in heath information systems or wearables. Otherwise, the firm considers device-approached technologies in the therapeutics, diagnostics, and digital health space in development and clinical phases. While the firm is open to all indications, cardiology, neurology, and surgery are areas of interest. 

The firm does not have any requirements of the management team. The firm will both lead and co-lead depending on the area of expertise. Board seating will be required when leading investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture arm of an innovation hub headquartered in California for life science, medtech, and technology companies invests in Pre-Seed and Seed stage biotech, device, and ag-tech companies in the U.S. The firm acts as a lead investor. For Pre-Seed rounds, typical check size falls between $250k-1M and for Seed rounds, typical check size falls between $1M-3M. For their main fund, it is not required for companies to go through the accelerator program, however the resources are available and encouraged 

In terms of life sciences and healthcare, the firm is interested in biotech and medical devices. For biotech, the firm is subsector agnostic, including drug development and bio tools, for device, the firm is open to all classes. The firm is also indication-agnostic. The firm typically looks at companies in pre-clinical stages. 

The firm requires companies to already be incorporated and have their CEOs to be fulltime. The firm may take a board seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A manufacturing company has a wide range of businesses including analytical instruments, medical devices, and industrial equipment. Recently, the company has been focusing on healthcare, specifically in clinical diagnostics and biomanufacturing. In April 2023, the company established a CVC (corporate venture capital) department and is looking for strategic partnerships with companies with cutting-edge technology that align with their businesses. The fund will be managed for 10 years with a total investment of $50M USD. So far, the venture arm has invested in 3 companies in the U.S. and Japan and is looking to expand their investments in the States, though they are open to meeting with global companies. The fund is looking to invest in Pre-Seed to Early rounds but may invest as far as Series A. Typical check size can range from $1-10M USD but can exceed if there is a particularly strong interest in a technology. 

In terms of healthcare, the venture arm is looking to invest in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but consumables as well.  

To attract investment from the venture arm, having a lead investor is desirable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A VC fund based in the U.S. invests in early-stage applied AI companies in healthcare, enterprise, and automation. The firm follows their thesis of partnering and investing in entrepreneurs who have a deep desire to use AI-enabled technology to tackle the most challenging problems in the given industries. The founder, a tech entrepreneur themself, started the fund with the idea of wanting to pay it forward towards startups that can make a large impact in the world. The firm can invest in Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K. The firm can lead investments as they like to be active investors, utilizing their strong network to help companies with operations, funding, commercialization, and more. 

In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics, and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets. 

The firm prefers to take a board seat however, it is not required. 

 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.